Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence

Aims Insulin therapy is indicated for people with Type 1 diabetes mellitus; however, treatment‐related weight gain and hypoglycaemia represent barriers to optimal glycaemic management. This study assessed the health economic value of maintained reductions in HbA 1c , BMI and hypoglycaemia incidence among the UK Type 1 diabetes population. Methods The Cardiff Type 1 Diabetes Model was used to estimate lifetime costs, life‐years and quality‐adjusted life‐years ( QALY s) for individuals with Type 1 diabetes at different baseline HbA 1c , BMI and hypoglycaemic event rates. Results were discounted at 3.5%, and the net monetary benefit associated with improving Type 1 diabetes management was derived at £20 000/ QALY gained. Per‐person outputs were inflated to national levels using UK Type 1 diabetes prevalence estimates. Results Modelled subjects with an HbA 1c of 86 mmol/mol (10.0%) were associated with discounted lifetime per‐person costs of £23 795; £12 649 of which may be avoided by maintaining an HbA 1c of 42 mmol/mol (6.0%). Combined with estimated QALY gains of 2.80, an HbA 1c of 42 mmol/mol (6.0%) vs. 86 mmol/mol (10.0%) was associated with a £68 621 per‐person net monetary benefit. Over 1 year, unit reductions in BMI produced £120 per‐person net monetary benefit, and up to £197 for the avoidance of one non‐severe hypoglyceamic event. Conclusions Maintained reductions in HbA 1c significantly alleviate the burden associated with Type 1 diabetes in the UK . Given the influence of weight and hypoglycaemia on health economic outcomes, they must also be key considerations when assessing the value of Type 1 diabetes technologies in clinical practice.